Dec. 22, 2015
On December 22, 2015 the Sihuan Pharmaceutical Holdings Group Ltd. announced that its subsidiary, Shandong XuanZhu Pharma, and Japanese RaQualia Pharma Inc. entered into a research collaboration agreement. The collaboration will focus on developing pre-clinical compounds for a specific ion channel target. Pursuant to the terms of the Agreement, RaQualia and the Group will work collaboratively to identify valuable drug candidates during the three-year collaboration period. The parties also agree to jointly promote the global market development for such candidates. The Group will be granted with exclusive rights to develop, manufacture and market the drug candidates in the Greater China Region and will share the income generated from markets outside of the Greater China Region.